腹膜癌病是胃癌最致命的转移模式之一，中位总生存期 (OS) 为 4 个月。到目前为止，姑息性全身化疗（pSC）是唯​​一推荐的治疗方法。本研究的目的是评估 CRS HIPEC 与 pSC 相比的潜在生存获益。根据 2024 年 3 月的 PRISMA 指南进行了系统评价。其中包括报告接受 CRS HIPEC 治疗的胃癌腹膜癌病患者的手稿。进行了荟萃分析，比较了 CRS HIPEC 组和 pSC 组之间的生存结果，主要结果是 OS 方面的比较。我们对比值比 (OR) 进行了随机效应荟萃分析。我们使用 Q2 统计数据评估异质性。在纳入的 24 篇论文中，1369 名患者接受了 CRS HIPEC，中位 OS 范围为 9.8-28.2 个月； 103 名患者接受了 pSC，中位 OS 范围为 4.9-8 个月。与姑息性全身化疗相比，CRS HIPEC 与显着增加的生存率相关（-1.8954（95% CI：-2.5761 至 -1.2146；p < 0.001）。与 pSC 相比，CRS HIPEC 可在胃癌腹膜转移中提供生存优势。

Peritoneal carcinomatosis is one of deadliest metastatic patterns of gastric cancer, being associated with a median overall survival (OS) of 4 months. Up to now, palliative systemic chemotherapy (pSC) has been the only recommended treatment. The aim of this study is to evaluate a potential survival benefit after CRS + HIPEC compared to pSC.A systematic review was conducted according to the PRISMA guidelines in March 2024. Manuscripts reporting patients with peritoneal carcinomatosis from gastric cancer treated with CRS + HIPEC were included. A meta-analysis was performed, comparing the survival results between the CRS + HIPEC and pSC groups, and the primary outcome was the comparison in terms of OS. We performed random-effects meta-analysis of odds ratios (ORs). We assessed heterogeneity using the Q2 statistic.Out of the 24 papers included, 1369 patients underwent CRS + HIPEC, with a median OS range of 9.8-28.2 months; and 103 patients underwent pSC, with a median OS range of 4.9-8 months. CRS + HIPEC was associated with significantly increased survival compared to palliative systemic chemotherapy (-1.8954 (95% CI: -2.5761 to -1.2146; p < 0.001).CRS + HIPEC could provide survival advantages in gastric cancer peritoneal metastasis compared to pSC.